Holdings A/s Novo's Net Worth

$1.51 Billion

Estimate Recalculated Jul 12, 2024 05:40PM EST

Who is Holdings A/s Novo?

Holdings A/s Novo has an estimated net worth of $1.51 Billion. This is based on reported shares across multiple companies, which include ALDER BIOPHARMACEUTICALS INC, Arcellx, Inc., Morphic Holding, Inc., Flexion Therapeutics Inc, REATA PHARMACEUTICALS INC, CoLucid Pharmaceuticals, Inc., ZS Pharma, Inc., Nkarta, Inc., Praxis Precision Medicines, Inc., Apollo Endosurgery, Inc., KalVista Pharmaceuticals, Inc., Inogen Inc, ANAPTYSBIO INC, Milestone Pharmaceuticals Inc., iRhythm Technologies, Inc., Verve Therapeutics, Inc., IO Biotech, Inc., Edgewise Therapeutics, Inc., NEVRO CORP, Mirum Pharmaceuticals, Inc., Ophthotech Corp., Harmony Biosciences Holdings, Inc., Cyteir Therapeutics, Inc., Corvus Pharmaceuticals, Inc., Aligos Therapeutics, Inc., Reneo Pharmaceuticals, Inc., Inozyme Pharma, Inc., Galecto, Inc., Eargo, Inc., Entasis Therapeutics Holdings Inc., Checkmate Pharmaceuticals, Inc., Galera Therapeutics, Inc., Bolt Biotherapeutics, Inc., SPRUCE BIOSCIENCES, INC., HTG MOLECULAR DIAGNOSTICS, INC, Akebia Therapeutics, Inc., MINERVA SURGICAL INC, OTONOMY, INC., Ra Pharmaceuticals, Inc., Disc Medicine, Inc., BIOMIMETIC THERAPEUTICS, INC., and Regado Biosciences Inc.

SEC CIK

Holdings A/s Novo's CIK is 0001388325

Past Insider Trading and Trends

2008 was Holdings A/s Novo's most active year for acquiring shares with 556 total transactions. Holdings A/s Novo's most active month to acquire stocks was the month of April. 2017 was Holdings A/s Novo's most active year for disposing of shares, totalling 50 transactions. Holdings A/s Novo's most active month to dispose stocks was the month of May. 2018 saw Holdings A/s Novo paying a total of $26,347,520.00 for 3,358,313 shares, this is the most they've acquired in one year. In 2016 Holdings A/s Novo cashed out on 11,406,518 shares for a total of $81,298,384.87, their largest year based on trade value.

Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!

ALDER BIOPHARMACEUTICALS INC No price found

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
3.2M
$10.00
3.2M
May 13
Form 3
0
0
No matching records found

Arcellx, Inc. (ACLX) Snapshot price: $66.02

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
4.02M
$15.00
4.02M
Feb 8
Form 3
0
0
No matching records found

Morphic Holding, Inc. (MORF) Snapshot price: $38.15

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
2.65M
$15.00
2.65M
Jun 28
Form 3
0
0
No matching records found

Flexion Therapeutics Inc No price found

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
-6.57%
-150.00K
$20.61
-$3,091,972.83
2.13M
Jun 18 - Jun 22
Form 4
+28.04%
500K
$17.00
$8,500,000.00
2.28M
Dec 17
Form 4
1.78M
$13.00
$9,000,004.00
1.78M
Feb 18
Form 3
0
0
No matching records found

REATA PHARMACEUTICALS INC No price found

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
0
0
Jun 22
Form 4
-9.33%
-61.00K
$25.11
-$1,531,925.90
592.79K
Jun 13 - Jun 14
Form 4
-25.39%
-222.50K
$25.71
-$5,719,778.64
653.79K
Jun 8 - Jun 12
Form 4
-9.27%
-89.50K
$28.24
-$2,527,394.13
876.3K
Jun 5 - Jun 7
Form 4/A
+28.77%
215.79K
965.79K
Jun 1
Form 4
750K
$11.00
$8,250,000.00
750K
Jun 1
Form 3
0
0
No matching records found